Tavexia Lifecare passes all four resolutions at 46th AGM

scanx
Reviewed by
Anirudha BScanX News Team
Key Highlights
  • Tavexia Lifecare passed all four resolutions at its 46th AGM
  • Special resolution approved material related party transactions up to ₹100 crore
  • Promoter votes of 15,460,794 were invalidated for the RPT resolution due to interest conflict
  • Mrs. Khushboo Vasudev re-appointed as independent director for a second five-year term
powered bylight_fuzz_icon
52396355

*this image is generated using AI for illustrative purposes only.

Tavexia Lifecare Limited held its 46th Annual General Meeting on September 30, 2026, passing all four proposed resolutions. The meeting was conducted via video conferencing and other audio-visual means, in compliance with SEBI regulations.

Key Resolutions Passed

The shareholders approved the adoption of audited standalone and consolidated financial statements for FY26. They also appointed statutory auditors to fill a casual vacancy caused by the resignation of previous auditors. A special resolution was passed to approve material related party transactions up to ₹100 crore. Additionally, Mrs. Khushboo Vasudev was re-appointed as an independent director for a second five-year term starting December 31, 2026.

Voting Results Summary

The voting process utilized remote e-voting and electronic voting during the meeting. The results for each resolution are detailed below:

Resolution Subject Nature Result Votes For (%) Votes Against (%)
1 Adoption of Accounts Ordinary Passed 99.997% 0.003%
2 Appointment of Auditors Ordinary Passed 99.997% 0.003%
3 Material RPT (₹100 Cr) Special Passed 99.995% 0.005%
4 Re-appointment of Director Special Passed 99.997% 0.005%

What the Numbers Show

A notable procedural detail emerged during the voting on Resolution 3, which concerned material related party transactions. One promoter shareholder, being an interested party, cast 15,460,794 votes. These votes were declared invalid and excluded from the count, as per regulatory norms requiring interested parties to abstain from voting on related party transactions. Despite this exclusion, the resolution passed with overwhelming support from non-promoter shareholders.

Attendance and Participation

A total of 57 members attended the virtual meeting. Of these, 19 members had already exercised their voting rights through remote e-voting prior to the meeting. No members cast votes through the electronic facility during the live meeting itself. The remaining 38 attendees did not exercise their voting rights. Overall, 100 members participated in the voting process via remote e-voting.

Historical Stock Returns for Sattva Sukun Lifecare

1 Day5 Days1 Month6 Months1 Year5 Years
+1.72%-0.84%+16.83%+61.64%+35.63%-68.62%

What specific business activities or projects will the ₹100 crore approved for material related party transactions fund in the coming fiscal year?

How will the re-appointment of Mrs. Khushboo Vasudev as an independent director influence Tavexia Lifecare's governance strategy and oversight of related party dealings?

What factors contributed to the resignation of the previous statutory auditors, and how might the new appointment impact future financial reporting transparency?

like19
dislike

Tavexia Lifecare board to decide on Meyonex acquisition on Oct 7

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • Board meeting scheduled for October 7, 2026, to decide on acquiring up to 60% equity in Meyonex Pharmaceuticals
  • Acquisition proposal initially approved on September 7, 2026, with subsequent due diligence authorized
  • Trading window closed from September 30, 2026, until 48 hours post-board meeting per SEBI regulations
  • Target company is Meyonex Pharmaceuticals Limited, an unlisted public entity
powered bylight_fuzz_icon
52247058

*this image is generated using AI for illustrative purposes only.

Tavexia Lifecare Limited has scheduled a board meeting for October 7, 2026, to deliberate on the proposed acquisition of up to 60% of the equity share capital of Meyonex Pharmaceuticals Limited. This decision follows preliminary evaluations conducted after an initial approval in September.

The meeting agenda specifically includes reviewing developments in the matter and determining the further course of action regarding the acquisition. Meyonex Pharmaceuticals is an unlisted public company. The board previously authorized designated representatives to undertake due diligence, valuation, and negotiations in relation to the deal during its meeting held on September 7, 2026.

Regulatory Compliance and Trading Window

In compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of Tavexia Lifecare was closed from September 30, 2026. The window will remain closed until 48 hours after the board meeting scheduled for the approval of un-audited financial results for the half year ended September 30, 2026. Designated persons and their immediate relatives are restricted from trading in the company's securities during this period.

Meeting Details

Item Detail
Meeting Date October 7, 2026
Primary Agenda Acquisition of up to 60% equity in Meyonex Pharmaceuticals
Target Company Meyonex Pharmaceuticals Limited (Unlisted)
Prior Approval Date September 7, 2026
Trading Window Close September 30, 2026

The board will also consider and transact any other business with the permission of the Chairperson. The intimation was filed with BSE Ltd under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Historical Stock Returns for Sattva Sukun Lifecare

1 Day5 Days1 Month6 Months1 Year5 Years
+1.72%-0.84%+16.83%+61.64%+35.63%-68.62%

What specific strategic synergies or therapeutic areas is Tavexia Lifecare targeting through the acquisition of Meyonex Pharmaceuticals?

How might the integration of an unlisted entity like Meyonex impact Tavexia's future financial reporting standards and valuation multiples?

Will the proposed acquisition trigger any mandatory open offer obligations or require additional regulatory clearances from the CCI?

like16
dislike

More News on Sattva Sukun Lifecare

1 Year Returns:+35.63%